AU2021205326B2 - SMARCA2-VHL degraders - Google Patents

SMARCA2-VHL degraders

Info

Publication number
AU2021205326B2
AU2021205326B2 AU2021205326A AU2021205326A AU2021205326B2 AU 2021205326 B2 AU2021205326 B2 AU 2021205326B2 AU 2021205326 A AU2021205326 A AU 2021205326A AU 2021205326 A AU2021205326 A AU 2021205326A AU 2021205326 B2 AU2021205326 B2 AU 2021205326B2
Authority
AU
Australia
Prior art keywords
compound
mmol
carcinomas
pharmaceutically acceptable
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021205326A
Other languages
English (en)
Other versions
AU2021205326A1 (en
Inventor
Abhisek Banerjee
Victor J. Cee
Ning Chen
Xiaofen Li
Ryan Paul Wurz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2021205326A1 publication Critical patent/AU2021205326A1/en
Application granted granted Critical
Publication of AU2021205326B2 publication Critical patent/AU2021205326B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021205326A 2020-01-10 2021-01-08 SMARCA2-VHL degraders Active AU2021205326B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959502P 2020-01-10 2020-01-10
US62/959,502 2020-01-10
PCT/US2021/012683 WO2021142247A1 (en) 2020-01-10 2021-01-08 Smarca2-vhl degraders

Publications (2)

Publication Number Publication Date
AU2021205326A1 AU2021205326A1 (en) 2022-07-21
AU2021205326B2 true AU2021205326B2 (en) 2026-06-11

Family

ID=74495106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021205326A Active AU2021205326B2 (en) 2020-01-10 2021-01-08 SMARCA2-VHL degraders

Country Status (7)

Country Link
US (1) US20230091042A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087658B1 (cg-RX-API-DMAC7.html)
JP (1) JP7706456B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021205326B2 (cg-RX-API-DMAC7.html)
CA (1) CA3167166A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022008487A (cg-RX-API-DMAC7.html)
WO (1) WO2021142247A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
MX2023001445A (es) * 2020-08-04 2023-05-08 Aurigene Oncology Ltd Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders

Also Published As

Publication number Publication date
JP7706456B2 (ja) 2025-07-11
WO2021142247A1 (en) 2021-07-15
JP2023510746A (ja) 2023-03-15
US20230091042A1 (en) 2023-03-23
MX2022008487A (es) 2022-08-02
EP4087658A1 (en) 2022-11-16
CA3167166A1 (en) 2021-07-15
AU2021205326A1 (en) 2022-07-21
EP4087658B1 (en) 2026-07-01